Company: RPTX
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030405
Chunk: 75

Company: Repare Therapeutics Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 75
---
 on Nasdaq. The expected term of our options granted to employees has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. With the adoption of ASU 2018-07, we applied the nonpublic entity practical expedient for calculating the expected term of non-employee awards, using the midpoint between the vesting date and the contractual term, which is consistent with the method used for employee awards. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. We have not paid, and do not anticipate paying, cash dividends on our common shares; therefore, the expected dividend yield is assumed to be zero. 

Recent Accounting Pronouncements

See note 2 to our annual consolidated financial statements appearing elsewhere in this Annual Report for a description of recently adopted accounting pronouncements and recently issued accounting pronouncements not yet adopted. 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk. 

Under SEC rules and regulations, because we are considered to be a “smaller reporting company”, we are not required to provide the information required by this item in this report. 

98

Item 8. Financial Statements and Supplementary Data. 

REPARE THERAPEUTICS INC. 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS 

    Page

    Report of Independent Registered Public Accounting Firm (PCAOB ID: 1263)
    100

    Consolidated Balance Sheets as of December 31, 2024 and 2023
    102

    Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2024 and 2023
    103

    Consolidated Statements of Shareholders’ Equity for the years ended December 31, 2024 and 2023
    104

    Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023
    105

    Notes to Consolidated Financial Statements
    106

99

Report of Independent Registered Public Accounting Firm

To the Shareholders and the Board of Directors of Repare Therapeutics Inc.

Opinion on the Financial StatementsWe have audited the accompanying consolidated balance sheets of Repare Therapeutics Inc. (the “Company”) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive